New hope for rare, Fast-Growing tumors: First-of-its-Kind trial launches
NCT ID NCT05746208
Summary
This study is testing whether a combination of two existing cancer drugs, lenvatinib and pembrolizumab, can help control a rare and aggressive type of neuroendocrine tumor. It will enroll 29 adults with a specific, fast-growing tumor type that has spread or cannot be removed by surgery. The main goal is to see how many patients' tumors shrink significantly from the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.